These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 15840750

  • 1. Effects of recombinant growth hormone on visceral fat accumulation: pilot study in human immunodeficiency virus-infected adolescents.
    Viganò A, Mora S, Manzoni P, Schneider L, Beretta S, Molinaro M, di Natale B, Brambilla P.
    J Clin Endocrinol Metab; 2005 Jul; 90(7):4075-80. PubMed ID: 15840750
    [Abstract] [Full Text] [Related]

  • 2. Impaired growth hormone secretion correlates with visceral adiposity in highly active antiretroviral treated HIV-infected adolescents.
    Viganò A, Mora S, Brambilla P, Schneider L, Merlo M, Monti LD, Manzoni P.
    AIDS; 2003 Jul 04; 17(10):1435-41. PubMed ID: 12824780
    [Abstract] [Full Text] [Related]

  • 3. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection.
    Engelson ES, Glesby MJ, Mendez D, Albu JB, Wang J, Heymsfield SB, Kotler DP.
    J Acquir Immune Defic Syndr; 2002 Aug 01; 30(4):379-91. PubMed ID: 12138344
    [Abstract] [Full Text] [Related]

  • 4. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation.
    Lo JC, Mulligan K, Noor MA, Schwarz JM, Halvorsen RA, Grunfeld C, Schambelan M.
    J Clin Endocrinol Metab; 2001 Aug 01; 86(8):3480-7. PubMed ID: 11502767
    [Abstract] [Full Text] [Related]

  • 5. Metabolic effects of a growth hormone-releasing factor in patients with HIV.
    Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S.
    N Engl J Med; 2007 Dec 06; 357(23):2359-70. PubMed ID: 18057338
    [Abstract] [Full Text] [Related]

  • 6. Long-term high-physiological-dose growth hormone reduces intra-abdominal fat in HIV-infected patients with a neutral effect on glucose metabolism.
    Hansen BR, Haugaard SB, Jensen FK, Jensen JE, Andresen L, Iversen J, Andersen O.
    HIV Med; 2010 Apr 06; 11(4):266-75. PubMed ID: 20002779
    [Abstract] [Full Text] [Related]

  • 7. Effects of insulin-like growth factor (IGF)-I/IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance.
    Rao MN, Mulligan K, Tai V, Wen MJ, Dyachenko A, Weinberg M, Li X, Lang T, Grunfeld C, Schwarz JM, Schambelan M.
    J Clin Endocrinol Metab; 2010 Sep 06; 95(9):4361-6. PubMed ID: 20610601
    [Abstract] [Full Text] [Related]

  • 8. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia.
    Mulligan K, Khatami H, Schwarz JM, Sakkas GK, DePaoli AM, Tai VW, Wen MJ, Lee GA, Grunfeld C, Schambelan M.
    J Clin Endocrinol Metab; 2009 Apr 06; 94(4):1137-44. PubMed ID: 19174500
    [Abstract] [Full Text] [Related]

  • 9. Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study.
    Andersen O, Haugaard SB, Flyvbjerg A, Andersen UB, Ørskov H, Madsbad S, Nielsen JO, Iversen J.
    Eur J Clin Invest; 2004 Aug 06; 34(8):561-8. PubMed ID: 15305891
    [Abstract] [Full Text] [Related]

  • 10. The effects of low-dose growth hormone in HIV-infected men with fat accumulation: a pilot study.
    Lo JC, Mulligan K, Noor MA, Lee GA, Schwarz JM, Grunfeld C, Schambelan M.
    Clin Infect Dis; 2004 Sep 01; 39(5):732-5. PubMed ID: 15356790
    [Abstract] [Full Text] [Related]

  • 11. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial.
    Koutkia P, Canavan B, Breu J, Torriani M, Kissko J, Grinspoon S.
    JAMA; 2004 Jul 14; 292(2):210-8. PubMed ID: 15249570
    [Abstract] [Full Text] [Related]

  • 12. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy.
    Rietschel P, Hadigan C, Corcoran C, Stanley T, Neubauer G, Gertner J, Grinspoon S.
    J Clin Endocrinol Metab; 2001 Feb 14; 86(2):504-10. PubMed ID: 11158000
    [Abstract] [Full Text] [Related]

  • 13. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.
    Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S.
    J Clin Endocrinol Metab; 2010 Sep 14; 95(9):4291-304. PubMed ID: 20554713
    [Abstract] [Full Text] [Related]

  • 14. Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections.
    Amato G, Mazziotti G, Di Somma C, Lalli E, De Felice G, Conte M, Rotondi M, Pietrosante M, Lombardi G, Bellastella A, Carella C, Colao A.
    J Clin Endocrinol Metab; 2000 Oct 14; 85(10):3720-5. PubMed ID: 11061530
    [Abstract] [Full Text] [Related]

  • 15. Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy.
    Brambilla P, Bricalli D, Sala N, Renzetti F, Manzoni P, Vanzulli A, Chiumello G, di Natale B, Viganò A.
    AIDS; 2001 Dec 07; 15(18):2415-22. PubMed ID: 11740192
    [Abstract] [Full Text] [Related]

  • 16. A randomized, placebo-controlled trial of nandrolone decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant human growth hormone as active reference treatment.
    Storer TW, Woodhouse LJ, Sattler F, Singh AB, Schroeder ET, Beck K, Padero M, Mac P, Yarasheski KE, Geurts P, Willemsen A, Harms MK, Bhasin S.
    J Clin Endocrinol Metab; 2005 Aug 07; 90(8):4474-82. PubMed ID: 15914526
    [Abstract] [Full Text] [Related]

  • 17. Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women.
    Holloway L, Butterfield G, Hintz RL, Gesundheit N, Marcus R.
    J Clin Endocrinol Metab; 1994 Aug 07; 79(2):470-9. PubMed ID: 7519191
    [Abstract] [Full Text] [Related]

  • 18. Changes in body composition of human immunodeficiency virus-infected males receiving insulin-like growth factor I and growth hormone.
    Ellis KJ, Lee PD, Pivarnik JM, Bukar JG, Gesundheit N.
    J Clin Endocrinol Metab; 1996 Aug 07; 81(8):3033-8. PubMed ID: 8768870
    [Abstract] [Full Text] [Related]

  • 19. Preferential loss of omental-mesenteric fat during growth hormone therapy of HIV-associated lipodystrophy.
    He Q, Engelson ES, Albu JB, Heymsfield SB, Kotler DP.
    J Appl Physiol (1985); 2003 May 07; 94(5):2051-7. PubMed ID: 12679354
    [Abstract] [Full Text] [Related]

  • 20. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone.
    Jensen PB, Hansen TB, Frystyk J, Ladefoged SD, Pedersen FB, Christiansen JS.
    Clin Nephrol; 1999 Aug 07; 52(2):103-9. PubMed ID: 10480221
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.